Clinical Trial

A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse PFA Technology for AF

Study acronym: DISRUPT-AF
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
The DISRUPT-AF Registry is an observational, prospective, multi-center, non-randomized, real-world registry designed to obtain clinical experience with the Farapulse Pulsed Field Ablation System for the treatment of atrial fibrillation (AF).
Protocol Amendment History 1 change
minor Completion pushed: 2027-01-30 -> 2028-01-30 2026-07-16
Trial Details
NCT Number NCT06335082
Lead Sponsor Heart Rhythm Clinical and Research Solutions, LLC
Collaborators: Boston Scientific Corporation
Conditions Atrial Fibrillation
Enrollment 10,000 participants
Start Date 2024-04-24
Primary Completion 2026-11-30 (estimated)
Study Completion 2028-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-23